Prevention of Anal Condyloma with Quadrivalent Human Papillomavirus Vaccination of Older Men Who Have Sex with Men

BACKGROUND: The quadrivalent human papillomavirus vaccine (qHPV) is FDA-approved for use in males 9 to 26 years old to prevent anogenital condyloma. The objective of this study is to determine if qHPV is effective at preventing anal condyloma among men who have sex with men (MSM) aged 26 years and o...

Descripción completa

Detalles Bibliográficos
Autores principales: Swedish, Kristin A., Goldstone, Stephen E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979673/
https://www.ncbi.nlm.nih.gov/pubmed/24714693
http://dx.doi.org/10.1371/journal.pone.0093393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979673/
https://www.ncbi.nlm.nih.gov/pubmed/24714693
http://dx.doi.org/10.1371/journal.pone.0093393

Ejemplares similares